NCT07400926

Brief Summary

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
2mo left

Started Dec 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Dec 2025Jul 2026

Study Start

First participant enrolled

December 17, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 3, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 10, 2026

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

February 27, 2026

Status Verified

February 1, 2026

Enrollment Period

6 months

First QC Date

February 3, 2026

Last Update Submit

February 24, 2026

Conditions

Open Angle Glaucoma (OAG)Ocular Hypertension (OH)

Keywords

GlaucomaOcular Hypertension

Outcome Measures

Primary Outcomes (1)

  • Successful implantation

    Proportion of subjects for which Investigator was able to successfully follow the Instructions For Use/Prescribing Information and correctly administer the model G2-TRIO travoprost intracameral implant 75mcg with the updated inserter

    1 day

Study Arms (1)

Model G2-TRIO

Subjects receive a Travoprost intracameral implant with the Model G2-TRIO

Combination Product: Travoprost

Interventions

TravoprostCOMBINATION_PRODUCT

Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)

Model G2-TRIO

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult subjects with OAG or OHT

You may qualify if:

  • Diagnosis of Open-angle glaucoma
  • years of age or older

You may not qualify if:

  • Subject who is breast-feeding or pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Glaukos Investigative Site

Kenosha, Wisconsin, 53140, United States

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-AngleOcular HypertensionGlaucoma

Interventions

Travoprost

Condition Hierarchy (Ancestors)

Eye Diseases

Intervention Hierarchy (Ancestors)

CloprostenolProstaglandins F, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Central Study Contacts

Study Director

CONTACT

949-739-8749ClinicalResearch@glaukos.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 3, 2026

First Posted

February 10, 2026

Study Start

December 17, 2025

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

February 27, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

US(1)